Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
fatty liver disease
Biotech
AstraZeneca drops MASH drug over disappointing data
AstraZeneca has ended work on one of its drugs for fatty liver disease after viewing disappointing data from a phase 2 study.
James Waldron
Nov 6, 2025 5:21am
Fierce Pharma
Big Pharma bets big on MASH with a new combo playbook
Oct 17, 2025 9:30am
FDA considers new liver trial endpoint, sending MASH shares up
Aug 28, 2025 11:25am
Roche launches liver fibrosis blood test for MASLD
May 7, 2025 10:30am
Researchers ID potential MASH target by disrupting mouse gene
Mar 13, 2025 1:52pm
Inventiva lays off 50% of staff to go all-in on MASH drug
Feb 11, 2025 7:30am
Fierce Pharma
Fierce Pharma
Fierce Pharma
Fierce Pharma
